



Potential to support research and increase awareness on rare diseases research by Eurordis

Dr. Andreas L. G. Reimann, MBA

Chief Executive, Mukoviszidose, Bonn, Germany

Member of Eurordis' Board of Directors

replacing and speaking on behalf of:

Yann Le Cam, MBA

Chief Executive, European Organisation for Rare Diseases, EURORDIS

Vice Chair, Committee for Orphan Medicinal Products, COMP/EMEA



EURORDIS

A patient-driven European alliance of patient organisations

- Founded in **1997** by 4 patient groups:
- Non Governmental Organisation, Not for Profit, Independent
- A membership based organisation:
 - **225 members in 23 countries**
 - Covers over 1000 rare diseases
 - Represents millions of **People Living With Rare Diseases**
- A pan-European active network:
 - Board 12 members. 8 countries. 8 patients or parents. All representatives of patients groups.
 - Over 60 volunteers from various patient groups are involved in Eurordis' activities through task forces, steering committees, etc
 - Over 400 patient groups have participated to Eurordis' activities in 2003-2004: projects, surveys, conference, trainings, experts...
- www.eurordis.org





EURORDIS


Mission

Eurordis' mission is
to build a strong pan-European **community**
of patient organisations and people living
with rare diseases, to be their **voice** at
the European level, and – directly or
indirectly –
to fight against the impact of rare diseases
on their lives



EURORDIS

The patient-centred Health Care-Value Chain





EURORDIS

Take home message 1

- It is the value to the individual patient, that counts when
 - providing health care services
 - doing research
 - developing new therapeutic options
- Moving from a product-centred to a patient-centred view!



EURORDIS


What patient organisations can do to foster research and awareness for rare diseases ?

An Overview of Actions by Patient Organisations based on a survey conducted by Eurordis between September-December 2003



18 countries involved


Q1. In which country are your headquarters located ?



Regions	Number of questionnaires analysed	% of total
Northern Europe		
Estonia	21	6
Denmark	20	5
Finland	1	0*
Netherlands	19	5
Sweden	12	3
Total Northern Europe	73	19
Western Europe		
Belgium	31	8
France	92	25
Great Britain	24	6
Ireland	6	2
Total Western Europe	153	41
Southern Europe		
Italy	37	10
Portugal	3	1
Spain	46	12
Total Southern Europe	86	23
Central / Eastern Europe		
Austria	1	0*
Czech Republic	1	0*
Germany	36	10
Hungary	12	3
Switzerland	9	2
Total Central / Eastern Europe	59	15
USA	1	1
Total	372	100

* Less than 0.5%

Origin of analysed questionnaires



ICO




Patient Org' Emphasis on research: room for improvement

EURORDIS

Specific activities

However: older groups are more often lobbyists, research grant makers and care providers




ICORD February 2005



EURORDIS

Funding: members & private donors

Sources of funding: percentage of organisations quoting source





EURORDIS

Strong patient organisations are...

- **Empowering** rare disease patient groups,
- **Advocating** rare diseases as a public health issue,
- **Raising awareness** for rare diseases
- **Improving access** to information, treatment and care
- **Encouraging good practices**
- **Fostering rare disease research**
- **Supporting development** of treatments/orphan drugs,
- **Improving quality of life** through patient support, social, welfare and educational services



EURORDIS

Take home message 2

- Direct support or funding of research is important but not the top priority for patient organisations yet.
- Funding comes from members and private donors mostly.
- Strong patient organisations are of essence





EURORDIS

Fostering awareness and research for rare diseases

"To achieve the quickest access to as many safe, efficient, and affordable, new treatments for all rare disease patients in the EU"

- Participating actively in the regulatory process
- Advocating in the interest of the RD-community
- Partnering with academia and industry
- Driving research projects
- Undertaking public-health research through patient-organisation networks
- Empowering patient organisations



EURORDIS

An evolving partnership with regulatory authorities

- Active Role at EMEA
 - COMP (2+1), COMP WG Interested Parties (3)
 - CHMP WG Patient Organisations (3)
- Providing patient & medical experts
 - Protocol Assistance: regular participation since 2004
 - Risk Benefit Assessment reports: first cases
 - Risk Management Programmes e.g. Thalidomide, ongoing
 - Over 50 rare disease patient representatives have taken part into EMEA activities in the last 5 years thanks to Eurordis and with EMEA support



EURORDIS

Advocacy

- Why?
 - To promote rare disease as a public health issue,
 - To raise rare diseases awareness of policy makers
 - To bring forward concrete proposals
- How?
 - Regular interaction with policy makers and other partners
 - Position Papers, Official Comments, Letters
 - Internal European Public Affairs Committee in place
- What?
 - EU public health policy & RD: EU Health Policy Forum, DG Health Rare Disease Task Force, European Patient Forum
 - EU drug policy: orphan drugs regulation, future paediatric drugs regulation, new pharmaceutical legislation
 - EU research policy & RD: FP6, FP7



EURORDIS

An ongoing example of research advocacy action


- **7th Framework Programme**: raising awareness on the need for more basic and clinical rare disease research, more EU public funding, more coordination, more competitive research, on key priorities
- Regular proposal and comments sent in 2004
- A recent Eurordis **Position Paper** based on collaborative work with the working group on research for the French Rare Disease Health Plan and further internal consultation with our European Public Affairs Committee
- A **dissemination** to key people and a broad dissemination through Eurordis' electronic newsletter in 5 languages
- A **Discussion Forum** on Eurordis Website, open to members and all interested parties



A common market = equal access to treatment ?

EURORDIS

As for the Eurordis survey 2003, EU Member states do not provide access to all orphan products authorised prior to January 1st 2004.





EURORDIS

Partnering with industry, academia and regulators

- **COMP Working Group of Interested Parties**
 - 3 representatives from EMEA, COMP, Eurordis, EBE, academia
- **Eurordis Round Table of Companies**
 - created End 2004, with initial membership of 15 companies and with two workshops each year on targeted topics and regular information,
- **European Platform for Patient Organisations, Science and Industry (EPPOSI)**



EURORDIS

Research project leader/partner

- **EuroBioBank (FP 5)**
 - Eurordis coordinates a European network of DNA, cells and tissue banks for RD with 16 partners including 12 Biological Resources Centres in 8 countries
 - Objective: making biological samples available to research
- **Orphan Platform 2004-2005 (EU FP6 Funding, leader: Segolène Aymé)**
 - Eurordis is a full partner
 - Objective: making information on ongoing rare disease research programmes available and strengthening co-operation with industry (OrphanXChange)
- **Further Projects in planning**



EURORDIS

Public health research through rare disease patient organisations

- **EurordisCare 1:**

- survey on **access to care**
- 17 MS, 6 rare diseases, 50 associations

- **EurordisCare 2:**

- Survey on **access to diagnosis**
- 21 MS, 9 rare diseases, 70 associations
- 12 languages
- 6000+ questionnaires filled by patients & families, being analysed



Empowering patient organisations


- “Understanding Clinical Trial Protocols” in 2004: 10 sessions for a total of 98 trainees, in partnership with Inserm
- “Understanding Clinical Trial Protocols” in 2005:
 - 4 additional sessions in France with Inserm;
 - Transfer to Spain in Partnership with Fondation Doctor Robert/ Autonomous University of Barcelona + Carlos III + Feder;
 - Ongoing discussion in Italy
- “Understanding Clinical Trial Protocols” in 2005: 2 pilot sessions for in depth 2 days training based on case study
- “How research works?” In 2005: 1 or 2 pilot seminars with Inserm. If successful will be transferred to other countries in following years.



EURORDIS

Take home message 3

- EURORDIS is an accepted partner of EMEA, academia and industry
- It directly fosters research focused on rare diseases
- and empowers patient-organisations to become drivers of progress



Added value to the community

- Rare diseases affect about 30 mio citizens of the EU
- Addressing their health needs has an impact on public-health
- RD: the case for EU-policy
- RD can act as „models“ for common diseases
- „Fall-out“ for more common diseases likely
- Developing RD-products makes Europe more competitive



EURORDIS

Conclusion

- Patients with RD know their needs
- Re-focusing research around these needs
- Patient organisations play a fundamental role in driving patient-centred research for their (own) research
- Win-Win: the entire community benefits



EURORDIS

European Rare Disease Conference



European Conference on Rare Diseases
2005

- 3rd European Rare Disease Conference (Copenhagen 2001, Paris 2003)
- 21-22 June 2005 in Luxemburg
- Commission DG Sanco/EU Presidency/Eurordis
- 300 participants
- 5 languages
- A tool to promote interaction between scientists, clinicians, policy makers, patient groups, media and to develop a common agenda for rare diseases



EURORDIS

For more information

Contact Eurordis : + 33 1 56 53 52 10

Yann Le Cam, Chief Executive Officer

**Fabrizia Bigniami - Therapeutic Development
Officer**

**Christina Black- Membership & Networking
Manager**

www.eurordis.org